Spinal Muscular Atrophy (SMA) Whole Blood

Order Name: SMA WB
Test Number: 5194936
Revision Date: 03/21/2023

TEST NAME		METHO	DDOLOGY	LOINC CODE	
Spinal Muscular Atrophy (SMA) Whole Blood See Test Notes					
SPECIMEN REQUIREMENTS					
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment	
Preferred	8.5 mL (3 mL)	Whole Blood	ACD Solution A or B (Yellow Top)	Room Temperature	
Alternate 1	8.5 mL (3 mL)	Whole Blood	EDTA (Lavender Top)	Room Temperature	
Alternate 2	1	Buccal swab	PurFlock buccal swab kit	Room Temperature	
Alternate 3	1	Saliva	Oragene Dx saliva kit	Room Temperature	
Instructions	Specimen Type: Whole blood or PurFlock buccal swab kit or Oragene Dx saliva kit Specimen Volume: 8.5 mL whole blood or PurFlock buccal swab kit or Oragene Dx saliva kit Mininum Volume: 3 mL whole blood or PurFlock buccal swab kit or Oragene Dx saliva kit Collection: Standard phlebotomy. Follow PurFlock buccal swab kit or Oragene Dx 500 saliva kit collection instructions. Do not eat, drink, smoke, or chew gum 30 min prior to collection. Specimen Storage: Maintain specimen at room temperature or refrigerate at 4C Do not freeze. Special Instructions: To test fetal specimens, including cordblood, order test code 481651, Spinal Muscular Atrophy (SMA), Fetal Analysis Test orders must include an attestation that the provider has the patient's informed consent for genetic testing. Cause for Rejection: Frozen or hemolyzed specimen; quantity not sufficient for analysis; improper container or blood specimens more than four days post draw.				

GENERAL INFORMATION		
Expected TAT	8 - 14 days In some cases, additional time may be required for confirmatory or reflex tests.	
Performing Labcorp Test Code	481630	
Notes	Labcorp Test Code: 481630 Methodology Copy number assessment of SMN1 exon 7 by quantitative polymerase chain reaction (qPCR); reflex testing to SMN2 copy number analysis is performed for individuals with 0 copies of SMN1. For carrier screening, when two copies of SMN1 are detected, allelic discrimination qPCR targeting c.*3+80T>G in SMN1 is performed. The presence or absence of c.*3+80T>G correlates with an increased or decreased risk, respectively, of being a silent carrier (2+0).	
Lab Section	Reference Lab	

Service provided by Labcorp Oklahoma, Inc. All Rights Reserved. © 2003 - 2025